Literature DB >> 35546637

Refractive and biometrical characteristics of children with retinopathy of prematurity who received laser photocoagulation or intravitreal ranibizumab injection.

Xiaofeng Lu1,2, Xianlu Zeng2, Miaohong Chen2, Zixin Fan2, Lei Zheng2, Ya Tian2, Shaochong Zhang2, Ji C He3, Guoming Zhang4.   

Abstract

PURPOSE: To investigate the refractive and biometrical developments of children with retinopathy of prematurity (ROP) who received laser photocoagulation (LP) or intravitreal ranibizumab injection as treatment.
METHODS: This case-control study involved cases with Zone II Stage 3 ROP. Fourteen children (28 eyes) who received single LP were included in the laser group, and 14 children (27 eyes) who received single intravitreal ranibizumab injection were included in the injection group. The mean age at operation was 37.00±1.72 and 36.36±1.66 weeks for the laser and injection groups, respectively (P=0.161), and refraction measurements and biometry were performed at the mean age of 5.00±1.63 and 5.00±0.94 years for the laser and injection groups, respectively (P=1.000). Spherical equivalent (SE) after mydriatic refraction and best corrected visual acuity (BCVA) were measured by refraction test. Central corneal thickness (CCT), anterior corneal surface curvature and curvature radius, anterior chamber depth (ACD), lens thickness (LT) and axial length (AL) were measured by biometry using the IOL Master700 biometric instrument (Carl Zeiss Meditec AG). The biometrical images were reanalysed using a self-developed program in MATLAB (R2016a, MathWorks, Inc.) to obtain additional eye parameters, including the curvatures of the posterior cornea and the anterior and posterior surfaces of the lens. SPSS (V.23.0) was used for statistical analysis. Independent sample t test was used to compare the eyeball biological and refractive state measures of the two groups, and Pearson correlation coefficient was used to evaluate the correlation between SE and the biological parameters.
RESULTS: 1. (1) Cornea-related parameters: CCT (0.54±0.04mm vs 0.55±0.02mm, P>0.05), anterior corneal surface curvature radius (7.56±0.26 mm vs 7.67±0.43mm, P>0.05) and posterior corneal surface curvature radius (6.82±0.27mm vs 6.79±0.42mm, P>0.05). (2) ACD (3.21 ± 0.25mm vs 3.22 ± 0.19mm, P>0.05). (3) Lens-related parameters: anterior lens surface curvature radius (10.04±0.89mm vs 9.82±1.08mm, P>0.05), posterior lens surface curvature radius (5.49±0.55mm vs 5.92±0.73mm, P<0.05) and LT (3.80±0.14mm vs 3.59±0.16mm, P<0.05). (4) AL (21.82±1.07 vs 22.68±1.61, P<0.05). (5) Parameters related to refractive state: SE (-2.43±3.56 vs -0.53±3.12, P<0.05) and BCVA (log MAR, 0.17±0.14 vs 0.21±0.18, P>0.05). 2. (1) The SE of children in the laser group was positively correlated with LT (r=0.438, P<0.05), negatively correlated with ACD (r=-0.437, P<0.05) and had no significant correlation with other eyeball biological indicators (P>0.05). (2) The SE of children in the injection group was negatively correlated with AL (r=-0.537, P<0.05), positively correlated with CCT (r=0.455, P<0.05) and had no significant correlation with other eyeball biological indicators (P>0.05).
CONCLUSION: LP and intravitreal ranibizumab injection as ROP treatments produce myopic refraction with increased degree of myopia in children who received LP than in children who received ranibizumab injection. The increased myopia after LP is due to the increases in LT and posterior lens curvature and a shallow ACD.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Axial length; Crystalline lens; Intravitreal injection; Laser photocoagulation; Myopia; Retinopathy of prematurity

Mesh:

Substances:

Year:  2022        PMID: 35546637     DOI: 10.1007/s00417-022-05663-0

Source DB:  PubMed          Journal:  Graefes Arch Clin Exp Ophthalmol        ISSN: 0721-832X            Impact factor:   3.535


  6 in total

1.  [Correlation between refraction and ocular biometry].

Authors:  O Touzeau; C Allouch; V Borderie; R Kopito; L Laroche
Journal:  J Fr Ophtalmol       Date:  2003-04       Impact factor: 0.818

2.  Risk factor analysis for long-term unfavorable ocular outcomes in children treated for retinopathy of prematurity.

Authors:  Fatih Mehmet Mutlu; Murat Küçükevcilioğlu; Osman Melih Ceylan; Halil Ibrahim Altınsoy; S Umit Sarıcı
Journal:  Turk J Pediatr       Date:  2013 Jan-Feb       Impact factor: 0.552

3.  Retinopathy of Prematurity.

Authors:  Alice L Bashinsky
Journal:  N C Med J       Date:  2017 Mar-Apr

4.  Treatment of type I ROP with intravitreal bevacizumab or laser photocoagulation according to retinal zone.

Authors:  B Mueller; D J Salchow; E Waffenschmidt; A M Joussen; G Schmalisch; Ch Czernik; Ch Bührer; K U Schunk; H J Girschick; S Winterhalter
Journal:  Br J Ophthalmol       Date:  2016-06-14       Impact factor: 4.638

Review 5.  Retinopathy of Prematurity: A Review of Current Screening Guidelines and Treatment Options.

Authors:  Emily C Broxterman; Denise A Hug
Journal:  Mo Med       Date:  2016 May-Jun

Review 6.  Review of effects of anti-VEGF treatment on refractive error.

Authors:  Helen A Mintz-Hittner; Megan M Geloneck
Journal:  Eye Brain       Date:  2016-06-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.